Karuna (NASDAQ:KRTX) nears merger with Bristol-Myers Squibb

Grafa03-14

Karuna Therapeutics (NASDAQ:KRTX) has disclosed a significant update in its merger process with Bristol-Myers Squibb, indicating the expiration of the waiting period under the Hart-Scott-Rodino ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2419606387?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-14 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2419606387","market":"us","top_or_hot":-1,"title":"Karuna (NASDAQ:KRTX) nears merger with Bristol-Myers Squibb","media":"Grafa","content":"<div>\n<p>Karuna Therapeutics (NASDAQ:KRTX) has disclosed a significant update in its merger process with Bristol-Myers Squibb, indicating the expiration of the waiting period under the Hart-Scott-Rodino ...</p>\n\n<a href=\"https://grafa.com/news/karuna--nasdaq-krtx--nears-merger-with-bristol-myers-squibb-196326?referralcode=A314DFDBE96C354756A893C6E3E02493\">Source Link</a>\n\n</div>\n","source":"grafa_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karuna (NASDAQ:KRTX) nears merger with Bristol-Myers Squibb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaruna (NASDAQ:KRTX) nears merger with Bristol-Myers Squibb\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-14 20:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://grafa.com/news/karuna--nasdaq-krtx--nears-merger-with-bristol-myers-squibb-196326?referralcode=A314DFDBE96C354756A893C6E3E02493><strong>Grafa</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Karuna Therapeutics (NASDAQ:KRTX) has disclosed a significant update in its merger process with Bristol-Myers Squibb, indicating the expiration of the waiting period under the Hart-Scott-Rodino ...</p>\n\n<a href=\"https://grafa.com/news/karuna--nasdaq-krtx--nears-merger-with-bristol-myers-squibb-196326?referralcode=A314DFDBE96C354756A893C6E3E02493\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0061475181.USD","symbol_name":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","start_time":0,"source_url":"https://grafa.com/news/karuna--nasdaq-krtx--nears-merger-with-bristol-myers-squibb-196326?referralcode=A314DFDBE96C354756A893C6E3E02493","article_id":"2419606387","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2419606387","pubTimestamp":1710420231,"sourceInfo":{"source_id":"grafa_news","name":"Grafa"},"weMediaInfo":null,"summary":"Karuna Therapeutics  has disclosed a significant update in its merger process with Bristol-Myers Squibb, indicating the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.This marks a crucial milestone, satisfying one of the conditions necessary for the merger's closure.On March 12, 2024, Karuna's shareholders showed their support for the merger agreement through a positive vote at a special meeting, moving the merger process closer to finalization, expected as soon as March 18, 2024.The merger between Karuna Therapeutics and Bristol-Myers Squibb is poised to heighten Karuna's operational and financial capabilities, given its anticipated assimilation as a wholly owned subsidiary of the pharmaceutical giant.","collect":0,"end_time":0,"defaultTopTitle":"grafa.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","BMY":"施贵宝","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","KRTX":"Karuna Therapeutics","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4581":"高盛持仓","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4112":"金融交易所和数据","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","NDAQ":"纳斯达克OMX交易所","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0237698245.USD":"富达环球地产基金A","BK4532":"文艺复兴科技持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4585":"ETF&股票定投概念","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BK4534":"瑞士信贷持仓",".IXIC":"NASDAQ Composite","BK4139":"生物科技","BK4007":"制药","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4535":"淡马锡持仓","BK4559":"巴菲特持仓","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC"},"translate_title":"卡鲁纳（纳斯达克：KRTX）接近与百时美施贵宝合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":1,".IXIC":1,"KRTX":1,"BMY":1},"content_text":"Karuna Therapeutics (NASDAQ:KRTX) has disclosed a significant update in its merger process with Bristol-Myers Squibb, indicating the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.\nThis marks a crucial milestone, satisfying one of the conditions necessary for the merger's closure.\nOn March 12, 2024, Karuna's shareholders showed their support for the merger agreement through a positive vote at a special meeting, moving the merger process closer to finalization, expected as soon as March 18, 2024.\nThe merger between Karuna Therapeutics and Bristol-Myers Squibb is poised to heighten Karuna's operational and financial capabilities, given its anticipated assimilation as a wholly owned subsidiary of the pharmaceutical giant.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2419606387"}